$NVCT

Cantor Fitzgerald Initiates Coverage on Nuvectis Pharma With Overweight Rating

Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing

Marlio Charles Mosseri, 10% Owner, on June 30, 2026, executed a purchase for 50,000 shares in Nuvectis Pharma (NVCT) for $916,000. Following the Form 4 filing with the SEC, Mosseri has control over a total of 3,295,897 common shares of the company, with 109,321 shares held directly and 3,186,576 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1875558/000110465926079793/xslF345X05/tm2619552-2_4seq1.xmlPrice: $19.64, Change: $+1.25, Percent Change: +6.80%

Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell

Nuvectis Pharma (NVCT) has priced 5 million shares of a secondary common stock offering at $20 per share, and anticipates $100 million in gross proceeds, the clinical stage biopharmaceutical company disclosed late Monday.Underwriters have been granted a 30-day option to purchase up to 750,000 additional shares.The company said it intends to use the net proceeds from the offering to continue to advance the development of certain drugs, as well as for hiring staff, capital expenditures, operating costs and other general corporate purposes.Shares of the company fell more than 18% in recent premarket trading activity Tuesday.Price: $23.12, Change: $-5.41, Percent Change: -18.96%

Nuvectis Pharma Launches Proposed Public Stock Offering

Nuvectis Pharma (NVCT) said Monday it has commenced an underwritten public offering of common stock, with all shares to be sold by the company.The company said it intends to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.Nuvectis said it plans to use the proceeds to advance development of NXP100, NXP200 and NXP900, hire additional personnel, fund capital expenditures and for general corporate purposes.Shares of the company fell over 20% in the after-hours trading.